Close

Clinical Trials at Waverly Hematology Oncology

Waverly Hematology Oncology is able to offer patients cutting edge therapy by participating in clinical trials. Patients will have access to state-of-the-art treatments normally found at large academic facilities while receiving personalized, community-based care.  Waverly Hematology Oncology is the only Triangle site of the SCOR (Southeast Clinical Oncology Research, Inc), a consortium of 22 practices in 5 states. Today’s clinical trial treatment may become tomorrow’s standard of care.

Please contact the Clinical Trials department for further information:
919-233-8585 or waverlyclinicaltrials@aoncology.com

ALL CANCERS:

Molecular Analysis for Therapy Choice (MATCH / EAY131)
Sponsor: National Cancer Institute
Status: ENROLLING
More Details

BREAST CANCER:

A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer (E5103)
Sponsor: National Cancer Institute
Status: Active but not currently accepting new participants
More Details

Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment. The TAILORx Trial (ECOG PACCT-1)
Sponsor: National Cancer Institute
Status: Active but not currently accepting new participants
More Details

A Phase III Clinical Trial Comparing the Combination of Docetaxel plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (NSABP-B49)
Sponsor: National Cancer Institute
Status: Active but not currently accepting new participants
More Details

A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamozifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer (NSABP-B42)
Sponsor: National Cancer Institute
Status: Active but not currently accepting new participants
More Details

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: “A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer” (SWOG 1007)
Sponsor: National Cancer Institute
Status: Active but not currently accepting new participants
More Details

Randomized Phase III Trials Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL / A011401)
Sponsor: National Cancer Institute
Status: ENROLLING
More Details

Asprin for Breast Cancer Study (ABC study)
Sponsor: ALLIANCE
Status: ENROLLING
More Details

A Randomized Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer (Monarch E / NASBP B-58)
Sponsor: Eli Lilly and Company and its representatives
Status: Active but not currently accepting new participants
More Details
Click here for study design.  

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo (B-59)
Sponsor: NSABP Foundation
Status: ENROLLING
More Details
Patient Education Slides

COLON CANCER:

Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent (EAQ162CD)
Sponsor: ECOG-ACRIN
Status: ENROLLING
More Details

LUNG CANCER:

A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-Small Cell Lung Cancer Subjects (KEYNOTE-407)
Sponsor: Merck
Status: Active but not currently accepting new participants
More Details

MULTIPLE MYELOMA:

A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles (the “CoMMpass Study” / MMRF-11-001)
Sponsor: Multiple Myeloma Research Foundation
Status: Active but not currently accepting new participants
More Details

OTHER:

CHRONIC LYMPHOCYTIC LEUKEMIA:

A Disease Registry for Patients with Chronic Lymphocytic Leukemia
Sponsor: Pharmacyclics LLC
Status: Active but not currently accepting new participants
More Details

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (A041702)
Sponsor: ALLIANCE
Status: ENROLLING
More Details

A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (EA9161)
Sponsor: ECOG-ACRIN
Status: ENROLLING
More Details